These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 19773087)

  • 1. Interferon-beta therapy for multiple sclerosis--is the injection site the relevant action site?
    Smith D
    J Neuroimmunol; 2009 Oct; 215(1-2):117-21. PubMed ID: 19773087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Innate immunity modulates autoimmunity: type 1 interferon-beta treatment in multiple sclerosis promotes growth and function of regulatory invariant natural killer T cells through dendritic cell maturation.
    Gigli G; Caielli S; Cutuli D; Falcone M
    Immunology; 2007 Nov; 122(3):409-17. PubMed ID: 17617156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis.
    Rudick RA; Ransohoff RM; Peppler R; VanderBrug Medendorp S; Lehmann P; Alam J
    Ann Neurol; 1996 Oct; 40(4):618-27. PubMed ID: 8871582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells.
    Korporal M; Haas J; Balint B; Fritzsching B; Schwarz A; Moeller S; Fritz B; Suri-Payer E; Wildemann B
    Arch Neurol; 2008 Nov; 65(11):1434-9. PubMed ID: 19001161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IFN-beta inhibits human Th17 cell differentiation.
    Ramgolam VS; Sha Y; Jin J; Zhang X; Markovic-Plese S
    J Immunol; 2009 Oct; 183(8):5418-27. PubMed ID: 19783688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of multiple sclerosis--1. New drugs may be effective but there still are frequent relapses].
    Svenningsson A; Andersson M; Olsson T
    Lakartidningen; 1998 Dec; 95(49):5623-7, 5630. PubMed ID: 9863300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-beta mechanisms of action in multiple sclerosis.
    Dhib-Jalbut S; Marks S
    Neurology; 2010 Jan; 74 Suppl 1():S17-24. PubMed ID: 20038758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial effect of interferon-beta treatment in patients with multiple sclerosis is associated with transient increase in serum IL-6 level in response to interferon-beta injection.
    Nakatsuji Y; Nakano M; Moriya M; Kishigami H; Tatsumi C; Tada S; Sadahiro S; Naka T; Mitani K; Funauchi M; Azuma T; Watanabe S; Kinoshita M; Kajiyama K; Yuasa Y; Kaido M; Takahashi MP; Naba I; Hazama T; Sakoda S;
    Cytokine; 2006 Oct; 36(1-2):69-74. PubMed ID: 17161613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Recent progress in treatment for multiple sclerosis].
    Kira J
    Rinsho Shinkeigaku; 2000 Dec; 40(12):1261-3. PubMed ID: 11464473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients.
    Weinstock-Guttman B; Bhasi K; Badgett D; Tamaño-Blanco M; Minhas M; Feichter J; Patrick K; Munschauer F; Bakshi R; Ramanathan M
    J Neuroimmunol; 2008 Dec; 205(1-2):113-25. PubMed ID: 18950872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrent injection site reactions from interferon beta 1-b.
    Samuel L; Lowenstein EJ
    J Drugs Dermatol; 2006 Apr; 5(4):366-7. PubMed ID: 16673806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe local skin reactions to interferon beta-1b in multiple sclerosis-improvement by deep subcutaneous injection.
    Nakamura Y; Kawachi Y; Furuta J; Otsuka F
    Eur J Dermatol; 2008; 18(5):579-82. PubMed ID: 18693165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous interferon-beta injections in patients with multiple sclerosis initiate inflammatory skin reactions by local chemokine induction.
    Buttmann M; Goebeler M; Toksoy A; Schmid S; Graf W; Berberich-Siebelt F; Rieckmann P
    J Neuroimmunol; 2005 Nov; 168(1-2):175-82. PubMed ID: 16126281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of injection site pain and injection site reactions in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a or 1b.
    Baum K; O'Leary C; Coret Ferrer F; Klímová E; Procházková L; Bugge J;
    Mult Scler; 2007 Nov; 13(9):1153-60. PubMed ID: 17967843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical response to interferon-beta-1a may be linked to low baseline circulating BDCA1 myeloid dendritic cells Differential role of circulating dendritic cells and CD4+ regulatory T-cells in relapsing-remitting multiple sclerosis: a 1-year longitudinal study.
    de Andrés C; Aristimuño C; Bartolomé M; de Las Heras V; Martínez-Ginés ML; Arroyo R; Fernández-Cruz E; Sánchez-Ramón S
    J Neuroimmunol; 2009 Jul; 212(1-2):112-20. PubMed ID: 19446889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel needle for subcutaneous injection of interferon beta-1a: effect on pain in volunteers and satisfaction in patients with multiple sclerosis.
    Jaber A; Bozzato GB; Vedrine L; Prais WA; Berube J; Laurent PE
    BMC Neurol; 2008 Oct; 8():38. PubMed ID: 18845005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different effects of simvastatin and interferon beta on the proteolytic activity of matrix metalloproteinases.
    Kieseier BC; Archelos JJ; Hartung HP
    Arch Neurol; 2004 Jun; 61(6):929-32. PubMed ID: 15210533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta.
    Comi G
    Clin Ther; 2009 Jun; 31(6):1142-57. PubMed ID: 19695384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dermal fibrosis and cutaneous necrosis after recombinant interferon-beta1a injection in a multiple sclerosis patient.
    Ozden MG; Erel A; Erdem O; Oztas MO
    J Eur Acad Dermatol Venereol; 2005 Jan; 19(1):112-3. PubMed ID: 15649205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increase of Ki-67+ natural killer cells in multiple sclerosis patients treated with interferon-β and interferon-β combined with low-dose oral steroids.
    Sanvito L; Tomita A; Chihara N; Okamoto T; Lin Y; Ogawa M; Gran B; Aranami T; Yamamura T
    J Neuroimmunol; 2011 Jul; 236(1-2):111-7. PubMed ID: 21652010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.